Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer

NCT06282575 is registered in ClinicalTrials.gov with Jazz Pharmaceuticals as lead sponsor.

NCT NCT06282575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06282575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer
Lead sponsor
Jazz Pharmaceuticals
Phase
Phase 3
Overall status
Recruiting
Start date
July 19, 2024
Completion date
April 1, 2030
Enrollment
286 (estimated)
Sites
185

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer